Doctors see surge in hand, foot and mouth cases this summer
There are usually some 200,000 reported cases of the viral illness each year, according to the American Medical Association, with spikes typical during summer and fall. But this summer, doctors say they're seeing even more than usual — although why remains unclear.
'I've been practicing pediatrics for about a decade. I don't think I've ever seen this many cases over a period of a few weeks,' Dr. Edith Bracho-Sanchez, a pediatrician at Columbia University Irving Medical Center in New York City, told The New York Times this week.
In Philadelphia, doctors told CBS News that the virus was spreading at summer camps, and a pool in the suburb of Chester was closed for a day after a reported infection.
"Each of our centers across the Philadelphia and surrounding county area are seeing multiple cases," Dr. Bob Czincila, medical director of Vybe urgent care, said.
Health officials in Maryland, New Jersey and Virginia, also told The Times that there have been more outbreaks in their states in 2025 compared to recent years. However, there is little concrete data because the Centers for Disease Control and Prevention does not require that doctors report cases.
The doctors have not hypothesized on the reason for the uptick in cases.
Hand, foot, and mouth disease commonly spreads at daycares, schools, and through water sources. The illness, which is common in children under the age of five, can cause a painful red rash of blister-like lesions, fever, and mouth sores.
Doctors say infection is usually not serious and people recover after a week or 10 days. Still, it is very contagious. Children can spread hand, foot and mouth disease from the day before the rash shows up and for several days after the rash appears, according to the Children's Hospital of Philadelphia.
People are often infected by contact with viruses in fecal matter, fluid from blisters, objects and surfaces with virus particles, and virus particles in the air after a person sneezes, coughs, or even just talks.
'Sometimes those small water-filled blisters can rupture and become shallow ulcers as well, especially in the mouth, which can be painful,' Dr. Terry Yen, a pediatrician and chief medical officer at Texas Children's Urgent Care, said.
To prevent infection, people should frequently wash their hands, disinfect surfaces, and avoid close contact with others.
If you are infected, most cases resolve on their own, but kids with a temperature above 103 degree Fahrenheit or who have rash that spreads to other parts of the body should see a doctor, Dr. Emily Boss, director of pediatric otolaryngology at Johns Hopkins Medicine, told The Times.
Treatment can help to alleviate uncomfortable symptoms. People can take pain relievers, although parents should never give aspirin to children.
Instead, kids can take Tylenol and Advil in the first three days of illness, when getting ahead of symptoms can make a major difference, Dr. Natasha Burgert, a pediatrician and national spokeswoman for the American Academy of Pediatrics, told The Times.
The mouth sores should be left to heal on their own. Try to eat soft foods and make sure to drink enough water to stay hydrated. The sores may make children not want to drink water.
With hand, foot and mouth disease, 'you get worried about children, especially younger children, who are not eating or drinking well becoming dehydrated. That would be a concern,' Yen warned.
That is why it is important to 'get children to drink more and help make them comfortable by treating the fevers and the pain.'
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Long Island soccer player returns to the field after beating cancer as a teen
A Long Island soccer player had to hang up his cleats after he was diagnosed with cancer, a disease that plagued both his mother and grandfather, but as CBS News New York's Krystle Rich reports, the American Soccer Club defender is back and stronger than ever.
Forbes
5 hours ago
- Forbes
UnitedHealth Stock Is Cracking Despite Strong Earnings—Here's What Wall Street Sees
UnitedHealth just reported billions in quarterly profit. Earnings were strong. The company sounded stable. And yet, Wall Street is dumping the stock. Shares are trading near multi-year lows, underperforming peers, and reacting poorly to each quarterly release. The market doesn't move like this for nothing—so what's really going on? Markets often sniff out risks long before they're made official. The headlines are piling up: government investigations, operational failures, and leadership questions, but the price has already started to discount something deeper. Investors are trained to react to numbers. But when structure breaks, the numbers are often the last to go. This isn't about a soft quarter. The model itself is cracking, and the market sees it. The way UnitedHealth generates earnings, the incentives behind its vertical integration, and the regulatory heat all point to fragility that isn't captured in consensus spreadsheets. The market is whispering what many investors don't want to admit: that something is changing here. And once trust fades, the re-rating isn't temporary. It's structural. UnitedHealth Stock: Big, Profitable, Misunderstood UnitedHealth trades with a market value of about $226 billion, against $400 billion in revenue for 2024, with 2025 revenue expected to reach mid‑$445 billion to $448 billion. Size doesn't really equal a safe company; it often hides the fragility beneath. Most investors can't describe how the business works. They see adjusted EPS. They don't question the mechanics. They assume that anything producing this much cash must be built to last. But what looks durable can rot from the inside. The core of UnitedHealth's engine is vertical integration. Optum decides on care, delivers it, and pays itself. One hand washes the other, all under the same roof. It's efficient when unexamined. But regulators are finally paying attention. When the payer, provider, and data all sit in one unit, it becomes harder to separate health outcomes from billing outcomes. Investors often mistake size for insulation. But complexity cuts both ways. When that model starts to wobble, through government probes, whistleblower claims, or unexplained earnings distortions, it doesn't usually collapse overnight. It slowly leaks. This is what we are witnessing. The price action is the tell. This isn't about sentiment anymore. It's about what the market now knows; the market no longer trusts what it thought it understood. You can see it is undone. Slowly at this point. But it's picking up. UnitedHealth Is In The Crosshairs Of The Regulators The Department of Justice now runs both criminal and civil investigations into UnitedHealth's Medicare Advantage billing, officially confirmed on July 24, 2025. Washington is targeting diagnostic coding and risk adjustment practices tied to higher payouts. A process investigators say may have involved pressure, bonuses, and algorithmic recommendations to staff for certain lucrative diagnoses. At the center is Optum, UnitedHealth's massive care delivery and analytics arm, which assigns diagnoses, delivers services, and influences payer reimbursement. That vertical structure underpinned margin expansion until it became a regulatory vulnerability. Congress and CMS are now eyeing those same incentives for bundled services that may prioritize profit over care. And according to multiple reports, lawmakers are drafting reforms to Medicare Advantage to clamp down on what they see as systemic abuse. This is more than a compliance issue. If enforcement leads to fines or limits on Optum's ability to steer claims, UnitedHealth loses both margin and narrative. The company disclosed a potential settlement cost of $1.6 billion tied specifically to these investigations. For investors, this isn't a question of past performance but future structure. If Washington forces a redesign in how payer, provider, and auditor relationships operate within Optum, valuation multiples change. You won't see regulatory risk on a spreadsheet. It's not in the line items. But it's in every fund manager's head. And the market is already pricing that doubt. Earnings Vs. Trust UnitedHealth keeps beating the numbers. But the market's not cheering anymore, and that should make investors stop to think. Second‑quarter 2025 adjusted EPS came in at $4.08, while GAAP net earnings per share were about $3.74, reflecting a 9‑10% spread. This isn't a one-off. The company has leaned on adjustments for several quarters, removing charges from cyberattacks, restructuring, litigation, and 'normalizing' expense items. Each quarter it gets harder to square the adjusted reality with the actual income statement. Investors have tolerated this because the stock used to respond. Now, even beats fall flat. The post-earnings reaction in July was strong, with headline numbers, and yet shares sank over 4%. It's not the earnings they're questioning. It's the whole premise. When the market no longer trusts the adjustment logic, the premium unwinds. At some point, 'adjusted' starts sounding like wishful thinking. That's a dangerous pivot for a stock that trades on perceived consistency. The issue here is credibility. And when credibility gets questioned in a complex, vertically integrated healthcare giant with active DOJ probes and massive opacity in its internal operations, the path forward narrows quickly. UnitedHealth's numbers still impress. But the market is no longer listening to the numbers alone. It's watching what they're trying to cover. Optum: The Black Box That Powered Growth At UnitedHealth For years, Optum was UnitedHealth's crown jewel. It gave the company vertical integration that most healthcare giants could only dream of. Run the insurer. Own the doctor's office. Control the pharmacy benefit manager. Route the claims. Capture every step of the dollar. Investors praised it as genius. Until now. Optum was built for margin expansion. By combining payer and provider, UnitedHealth collapsed the value chain into itself. But that same structure is now drawing fire. Regulators are asking whether a company can truly manage care outcomes and approve and profit from the services being recommended. This questions their entire integration strategy. What used to be pitched as 'scale and efficiency' now looks like opacity. Good luck getting through an Optum report without needing aspirin halfway. It's all intentional. In a market that once rewarded complexity, investors are shifting toward simplicity and transparency. Optum is the opposite. Here's the rub: the more essential Optum is to UnitedHealth's story, the more exposed the company becomes to scrutiny. Break the chain or just shake investor faith in it and the premium vanishes. Optum was once the crown jewel. Now it's the bullseye. The Cyberattack Was A Wake-Up Call At UnitedHealth When Change Healthcare, an Optum subsidiary, was hit by a massive ransomware attack earlier this year, most investors treated it as a one-off disruption. It wasn't. It was a systemic failure that revealed how fragile UnitedHealth's infrastructure had become and how slow its leadership was to respond. The breach paralyzed billing and claims systems for weeks across the U.S. healthcare network. Providers couldn't get paid. Pharmacies stalled. Patients were caught in the middle. For a company that sells itself on reliability and integration, the collapse of a core system fully exposed them to operational risk. But the real damage was reputational. CEO Andrew Witty's delayed response and lack of transparency during the fallout shook investor confidence. For a business model that depends on centralized control, a failure of this scale felt like the opposite of control. The market didn't punish the stock immediately, but the tone shifted. Since the hack, UnitedHealth stock has lagged peers, failed to respond to buybacks, and sold off post-earnings despite beats, indicating trust erosion. In healthcare, operational execution is the product. And the cyberattack told the market what the earnings couldn't: UnitedHealth may be bigger than ever, but its foundation isn't as solid as the numbers suggest. Defensive Stocks Are No Longer Safe Havens Investors once treated UnitedHealth like a bond proxy. It was dependable, defensive, and cash-rich, perfect in a zero-rate world, but the world has moved on. And the assumptions that supported its premium are unraveling with it. But investors have moved on. Higher rates change everything. Safety no longer commands a valuation premium. If anything, it draws sharper scrutiny. Now, capital seeks efficiency and flexibility. It rotates out of perceived stability the moment cracks appear. That's exactly what's happening with UnitedHealth. It's mainly about multiples. Stocks like UnitedHealth were priced on the assumption that growth would stay steady, margins wouldn't come under pressure, and regulators would remain passive. That's no longer the case. Every part of the thesis, from Medicare Advantage economics to Optum's integration, is under review. And the old multiple doesn't hold under new conditions. At 9 to 10 times forward earnings, UnitedHealth stock is still priced for control. But what happens if growth slows, scrutiny increases, and earnings quality erodes? That multiple doesn't hold when earnings wobble and faith erodes. And that's what we're starting to see. The idea that defensive means safe no longer applies. In a world where capital costs more and scrutiny cuts deeper, structural risk matters more than past predictability. And UnitedHealth is showing investors what happens when they confuse size for safety. Market Behavior Is Telling The market is speaking louder than the press release. UnitedHealth's earnings keep beating expectations, yet the stock keeps bleeding. After the Q2 2025 print, shares opened higher and then reversed, again indicating doubt from the market. Buybacks, once the reliable support mechanism, are falling flat. As of the April 2025 10‑Q, the board authorized repurchasing 27 million shares, not a dollar amount. Share count & price suggest a rough upper bound of ~$13 billion (assuming ~$500/share), but no official dollar figure exists. The tape hasn't cared. Investors aren't paying for stability anymore. They're questioning the model, and the price is reflecting it. This keeps happening. Strong numbers, weak tape. That's no coincidence. The market is reacting to what those earnings might not be showing. When price action diverges consistently from headline strength, something underneath is shifting. You don't need management to confirm what the price already knows. Scenarios Investors Must Weigh Every investor in UnitedHealth needs to face a simple question: what exactly is being priced in? The stock is still valued like nothing structurally will change. That's the best-case scenario: a regulatory slap on the wrist, no breakup, and margins protected. But cracks like these don't usually stop there. The base case is more uncomfortable. It assumes the DOJ and CMS probes gain traction, triggering forced disclosures, tighter reporting standards, and some form of operational reform. That alone could compress margins across Optum, weaken pricing power, and delay capital returns. It would also likely lower the multiple as the market stops assuming permanence in a business model that's now up for review. The worst case? A permanent re-rating. If the government cracks down on how care is authorized and reimbursed, if whistleblower cases uncover deeper abuses, or if investors lose trust in Optum's structure entirely, then UnitedHealth becomes less of a cash machine and more of a litigation risk. That would mean sustained outflows, ESG scrutiny, and index pressure. Right now, the stock trades like the best-case scenario is a given. That's a mistake. Risk is what you don't see coming, and the market has a habit of mispricing structural changes until they happen. UnitedHealth Stock Is Breaking For A Reason UnitedHealth has long benefited from scale, opacity, and the assumption that healthcare complexity equals safety. That illusion is fading. The stock is breaking not because of a single quarter or a bad headline, but because the structure that powered its dominance is now under the microscope. When investors start asking the right questions, eventually price always does. That's what's happening here. The DOJ, CMS, and media aren't just circling; they're probing a business model that was built on internal leverage and integration. When that's challenged, the numbers don't matter as much as the narrative. And UnitedHealth is losing control of its narrative. This isn't a bad value call. It's something deeper—the kind of unraveling that rewrites the whole thesis. Markets don't punish giants like this without reason. When scrutiny hits complexity, it always takes time, but it always resets expectations. UnitedHealth isn't priced for scrutiny. And when the foundation cracks, the market doesn't wait for permission to react; it already has.
Yahoo
13 hours ago
- Yahoo
New York has increased PFAS regulations as understanding has improved
Aug. 2—PFAS, a class of chemicals used to make nonstick cooking pans and waterproof clothing among hundreds of other applications, have become a serious health concern for officials across the country and in New York. PFAS, formally per- and polyflouroalkyl substances, are a class of chemicals that were heavily used from the 1940s to the late 2000s, although they persist in some applications to this day. Produced by companies like 3M, contamination can come from a variety of sources and typically results in contamination of the water table. They're known as 'forever chemicals' because there's no way to fully remove them from the water or soil they contaminate, and they don't break down fast enough to disappear over even centuries. They build up in the environment including plants and animals, causing health problems for them and also moving up the food chain. People who consume high levels of PFAS, or a smaller volume over a long period of time, can develop rare cancers, pre-eclampsia or a whole host of other chronic illnesses and diseases. In 2016, New York was one of the first states to urge the federal Environmental Protection Agency to acknowledge that PFAS contamination is a major concern — joined with Vermont and New Hampshire, they pushed the EPA to implement its first health advisory for PFAS consumption later that year. New York was the first state in the country to regulate PFAS, specifically the chemical perflourooctanoic acid or PFOA, according to the state Department of Environmental Protection. Officials took a wide survey of businesses, fire departments, fire training centers and federal Department of Defense facilities that year as well. State DEC officials collected 25,000 gallons of PFAS-containing firefighting foam up to 2018. In 2016, federal officials acknowledged that Fort Drum in Jefferson County had contaminated water near the Wheeler-Sack Army Airfield, resulting in the closure of nearly a half-dozen on-post water wells and a multi-million dollar federal grant to restore water sufficiency on post. In 2018, officials in New York were expressing disappointment with federal efforts to regulate and address PFAS. The EPA maintains a list of over 100 contaminants that are proven to harm human health, but officials have identified over 80,000 potentially toxic substances to be concerned about. "The federal government is charged with having a monitoring system to potentially add other chemicals to the ones we are required to test, but the EPA has not been moving fast enough," said Brad J. Hutton, former deputy commissioner for the state Public Health Office, speaking with the Watertown Daily Times in 2018. Action has come since then. In 2019, the EPA launched a PFAS action plan, outlining a roadmap for addressing chemical contamination in water and soil. In January of 2024, the EPA moved to ban nearly 330 'inactive' PFAS compounds from use or processing without an agency review, effectively taking the substances off the market. Inactive substances are those that aren't used in any major manufacturing, import or export operations in any U.S. territories. In April 2024, the EPA finalized a rule regulating six PFAS contaminants, including PFOA. The EPA also designated PFOA and PFOS, another similar compound, as hazardous to human health under the terms of the federal 'Superfund' law, allowing for cleanup and cost recovery from polluters. Questions arose in 2025 over whether the Trump administration would change or drop any of the new regulations adopted after his first term ended in 2021, and in May, the new EPA administrator and former New York gubernatorial candidate Lee Zeldin announced the agency would keep the Biden-era restrictions for PFOA and PFOS, another PFAS chemical, but would drop regulations and reconsider findings for four other substances including PFNA and HDFO-DA. The latter substance is known colloquially as 'GenX' and was a next-generation replacement to more harmful substances like PFOA. 'GenX' was later found to be similarly harmful to human health, and is similarly able to persist in the environment. "We are on a path to uphold the agency's nationwide standards to protect Americans from PFOA and PFOS in their water," Zeldin said. "At the same time, we will work to provide common-sense flexibility in the form of additional time for compliance. This will support water systems across the country, including small systems in rural communities, as they work to address these contaminants. EPA will also continue to use its regulatory and enforcement tools to hold polluters accountable." Zeldin pushed the compliance deadline for the new regulations, and promised to establish an outreach program focused on reaching noncompliant water systems, especially those in rural and small communities, to connect them with resources to bring their projects into compliance with the new rules. The initial rules required water systems to properly filter and remove the six contaminants by 2029, but the changes made by Zeldin push the broad deadline for PFOA and PFOS compliance to 2031. The EPA also has plans to establish an exemption framework to give noncompliant systems even more time to fix their systems, but the specifics for that aren't out yet. That move was lauded by some water district officials, including the Association of State Drinking Water Administrators Director, Alan Roberson. "With the current compliance date of 2029, states and water systems are struggling with the timeframes to complete the pilot testing, development of construction plans, and building the necessary treatment improvements. EPA's proposed extension of the compliance date and increased technical assistance will address the number of systems that would be out of compliance in 2029 due to not being able complete all of these tasks on time," Roberson said. Most of these changes aren't official yet — the EPA still has to introduce the new rules and usher them through the process, which could be done as early as the spring of next year. Solve the daily Crossword
